EGFR and non-small cell lung carcinoma: An enduring puzzle in clinical GB research has been the robust data showing that EGFR, mutated or just EGFR overexpressed, commonly drives growth in both NSCLC and GB, yet older, non-osimertinib EGFR inhibitors such as erlotinib and gefitinib anti-EGFR treatments commonly benefit in NSCLC, but have utterly failed to benefit in GB [13].